BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (212 d 08:34 ago) – Posting: # 23103
Views: 1,051


The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!

Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,478 posts in 4,708 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 8 identified bots]).
Forum time: 21:08 CET (Europe/Vienna)

I think it is much more interesting to live with uncertainty
than to live with answers that might be wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz